ANTICOAGULATION WITH DIRECT ORAL ANTICOAGULANTS BEYOND CLINICAL RECOMMENDATIONS: DIFFICULT CHOICE OF CLINICIANS AND PERSONALIZED APPROACH TO TREATMENT


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

This article describes an unusual clinical case, requiring rely on own expert’s opinion (and literature data) to get out of the difficult situation as in the present clinical observation - the combination of high risks of thromboembolic and hemorrhagic events.

Толық мәтін

Рұқсат жабық

Авторлар туралы

D. Napalkov

FSBEI HE "First MSMU n.a. I.M. Sechenov" of RMH

Email: dminap@mail.ru
Moscow

A. Sokolova

FSBEI HE "First MSMU n.a. I.M. Sechenov" of RMH

MD, Prof. at the Department of Faculty Therapy № 1 of the Medical Faculty Moscow

Әдебиет тізімі

  1. Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H.-C, Hacke W., Oldgren J., Sinnaeve P., Camm A.J., Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-507.
  2. Avezum A., Lopes R.D., Schulte P.J., Lanas F., Gersh B.J., Hanna M., Pais P., Erol C., Diaz R., Bahit M.C., Bartunek J., De Caterina R., Goto S., Ruzyllo W., Zhu J., Granger C.B., Alexander J.H. Apixaban in compared with warfarin in patients with atrial fibrillation and valvular heart disease: Findings from the ARISTOTLE trial. Circulation. 2015;132:624-32.
  3. Ezekowitz M.D., Parise H., Nagarakanti R., Noack H., Brueckmann M., Clemens A., et al. Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial. J. Am. Coll. Cardiol. 2014 63(Suppl. 12):A325.
  4. Breithardt G., Baumgartner H., Berkowitz S.D., Hellkamp A.S., Piccini J.P, Stevens S.R., Lokhnygina Y., Patel M.R., Halperin J.L., Singer D.E., Hankey G.J., Hacke W., Becker R.C., Nessel C.C., Mahaffey K.W., Fox K.A., Califf R.M. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur. Heart J. 2014;35: 3377-85.
  5. January C.T, Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. Jr., Conti J.B., Ellinor P.T., Ezekowitz M.D., Field M.E., Murray K.T., Sacco R.L., Stevenson W.G., Tchou P.J., Tracy C.M., Yancy C.W. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-267.
  6. Eikelboom J.W, Connolly S.J., Brueckmann M., Granger C.B., Kappetein A.P, Mack M.J., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N. Engl. J. Med. 2013;369:1206-14.
  7. Fang M.C., Go A.S., Chang Y., Borowsky L.H., Pomernacki N.K., Udaltsova N., Singer D.E. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J. Am. Coll. Cardiol. 2011;58:395-401.
  8. Westenbrink B.D., Alings M., Connolly S.J., Eikelboom J., Ezekowitz M.D., Oldgren J., Yang S., Pongue J., Yusuf S., Wallentin L., van Gilst W.H. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J. Thromb. Haemost. 2015; 13(5):699-707.
  9. Lip G.Y.H., Lane D.A. Matching the NOAC to the patient: Remember the modifiable bleeding risk factors. J. Am. Coll. Cardiol. 2015;66(21):2282-4.
  10. Sherwood M.W, Nessel C.C., Hellcamp A.S., Mahaffey K.W., Piccini J.P, Suh E.Y., Becker E.C., Singer D.E., Halperin J.L., Hankey G.J., Berkowitz S.D., Fox K.A., Patel M.R. Gastrointestinal bleeding in patients with patients treated rivaroxaban or warfarin: ROCKET-AF trial. J. Am. Coll. Cardiol. 2015;66(21):2271-81.
  11. Напалков Д.А., Соколова А.А. Алгоритм индивидуального выбора нового перорального антикоагулянта у пациентов с неклапанной фибрилляцией предсердий на основе имеющейся доказательной базы. Эффективная фармакотерапия. 2015;34:24-30.
  12. De Caterina R., Andersson U., Alexander J.H., Al-Khatib S.M., Bahit M.C., Goto S., Hanna M., Held C., Hohnloser S., Hylek E.M., Lanas F., Lopes R.D., Lopez-Sendon J., Renda G., Horowitz J., Granger C.B., Wallentin L.; ARISTOTLE investigators. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the ARISTOTLE trial. Am. Heart J. 2016;175:175-83.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2016